用于治疗精神障碍的哌嗪取代的苯并噻吩

本申请涉及作为依匹哌唑的前体药物的新化合物。本发明的新化合物在施用到受试者后，通过一个或多个代谢过程进行化学转化，以在体内释放出活性药剂。以Rexulti（注册商标）销售的依匹哌唑是一种非典型抗精神病药物，适合用作抗抑郁药的辅助疗法，用于治疗成人的重性抑郁障碍（MDD）和成人及13岁以上儿童患者的精神分裂症。#imgabs0# The present application relates to novel compounds of formula (I) which are prodrugs of brexpiprazole. The novel compounds of the inven...

Full description

Saved in:
Bibliographic Details
Format Patent
LanguageChinese
Published 22.08.2025
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:本申请涉及作为依匹哌唑的前体药物的新化合物。本发明的新化合物在施用到受试者后，通过一个或多个代谢过程进行化学转化，以在体内释放出活性药剂。以Rexulti（注册商标）销售的依匹哌唑是一种非典型抗精神病药物，适合用作抗抑郁药的辅助疗法，用于治疗成人的重性抑郁障碍（MDD）和成人及13岁以上儿童患者的精神分裂症。#imgabs0# The present application relates to novel compounds of formula (I) which are prodrugs of brexpiprazole. The novel compounds of the invention, upon administration to a subject, undergo chemical conversion by one or more metabolic processes to release an active pharmacological agent in vivo. Brexpiprazole, sold under the Rexulti (registered trademark), is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults and the treatment of schizophrenia in adults and pediatric patients ages 13 years and older.
Bibliography:Application Number: CN20248006469